Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Hospital Gregorio Marañón, Madrid, Spain.
Br J Haematol. 2021 Aug;194(3):537-541. doi: 10.1111/bjh.17506. Epub 2021 May 15.
Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Español de Trombocitopenia Inmune (GEPTI)].
感染是导致免疫性血小板减少症 (ITP) 患者复发的已知诱发因素之一。严重急性呼吸综合征冠状病毒 2 型 (SARS-CoV-2) 感染有时可因炎症过度激活导致外周血小板破坏增加而导致血小板减少症。目前,我们尚不清楚 SARS-CoV-2 感染是否会改变慢性或持续性 ITP 的自然病程,或者 ITP 患者的既往免疫抑制是否会影响该人群中 2019 年冠状病毒病 (COVID-19) 的发生率和严重程度。本研究是由西班牙 ITP 小组 [Grupo Español de Trombocitopenia Inmune (GEPTI)] 通过观察性、多中心、全国性的 32 例既往存在 ITP 且随后发生 SARS-CoV-2 感染的成年患者系列研究收集的。